March 29, 2017 4:24 AM ET


Company Overview of Shield Therapeutics plc

Company Overview

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease. Its products pipeline includes PT20, a novel iron-based phosphate binder for the treatment of hyperphosphatemia related to chronic kidney disease (CKD); PT30 and PT40 that are intravenous iron formulations; and Feraccru to treat patients with IDA related to CKD and other indications. The company was founded in 2008 and is based in Gateshead Quays, the United Kingdom.

Northern Design Centre

3rd Floor

Studio 6

Baltic Business Quarter

Gateshead Quays,  NE8 3DF

United Kingdom

Founded in 2008

14 Employees


44 1915 118 500

Key Executives for Shield Therapeutics plc

Co-Founder, Chief Executive Officer and Director
Age: 48
Total Annual Compensation: 418.0K GBP
Compensation as of Fiscal Year 2015.

Shield Therapeutics plc Key Developments

Shield Therapeutics plc Announces Resignation of Richard Jones as a Director and Company Secretary

Shield Therapeutics plc announced the resignation of Richard Jones as a director and company secretary of the company on 27 January 2017. The company has appointed Capita Registrars Limited as company secretary from 27 January 2017.

Shield Therapeutics plc Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Shield Therapeutics plc Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Richard Jones to Leave Shield Therapeutics plc as Chief Financial Officer in Early 2017

Shield Therapeutics plc announced that Richard Jones, Chief Financial Officer, will leave the Group in early 2017 to pursue a new opportunity. Until his departure Richard will continue as a Board member and Shield's Chief Financial Officer, with a focus on progressing key commercialization work streams as well as facilitating an orderly transition.

Similar Private Companies By Industry

Company Name Region
Abbey Pharma Limited Europe
Absynth Biologics Limited Europe
Acacia Pharma Limited Europe
AccentBio Ltd. Europe
Aclar Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shield Therapeutics plc, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at